Biosimilar Monoclonal Antibody Market
Report ID: SQMIG35A3304
Report ID: SQMIG35A3304
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35A3304 |
Region:
Global |
Published Date: February, 2026
Pages:
157
|Tables:
150
|Figures:
78
Global Biosimilar Monoclonal Antibody Market size was valued at USD 689.5 Million in 2024 and is poised to grow from USD 742.59 Million in 2025 to USD 1344.24 Million by 2033, growing at a CAGR of 7.7% during the forecast period (2026-2033).
The monoclonal antibodies that are used as drug biosimilars have increased significantly as the original products are going to come off patent and as health care organizations look for lower cost alternatives, that are clinically comparable to the original product, to save money. Cost containment is the most important factor in driving the use of these products. These biosimilars are nearly exact copies of the complex protein drugs currently used to treat cancer, autoimmune conditions and other rare diseases, and they represent one of the highest priced items found on a formulary that will be moved by the introduction of lower cost options.
The development of these biosimilars started with the development of generics to the small molecule drugs, which resulted in the establishment of a regulatory framework for the approval of biologic medicines in Europe and the United States, and examples of the successful use of biosimilars in both regions. As more biosimilars have been approved in Europe and the United States, hospitals and insurance companies can negotiate for lower prices for the biosimilars, which will further contribute to the usage of these products.
For example, the use of infliximab in Europe has been significantly impacted by the ability of the hospitals to enter tender contracts, which have resulted in significant reductions in the price of infliximab and an increase in the number of patients that receive infliximab treatment. Thus, demonstrating that increased competition increases overall access to care for patients.
How is AI Accelerating Development Timelines in the Biosimilar Monoclonal Antibody Market?
Artificial Intelligence is expediting the development of monoclonal antibody biosimilars by enhancing the identification of optimal candidates through a streamlined process of candidate selection, creating computerized models of manufacturability, and reducing the time required to complete the design-create-test-learn cycle (DCT).
Three important features of the system developed by AI-based systems include the following sequence-aware design tools are utilized to create feasible variants; predictive process models are employed that provide estimated expression and stability of produced antibodies; AI-guided optimization has been integrated with laboratory automation. Currently, many large developers of biologics and technology companies have turned to these processes to expedite their experimental cycles while also mitigating the risks related to manufacturing scale-up. As the market requires the ability to manufacture biosimilars that match or exceed the quality of the reference drugs while controlling the associated cost of production, AI has the potential to improve productivity and reduce time to market by enabling the development of mAb competitors.
Market snapshot - 2026-2033
Global Market Size
USD 689.5 Million
Largest Segment
Rituximab Biosimilars
Fastest Growth
Trastuzumab Biosimilars
Growth Rate
7.7% CAGR
To get more insights on this market click here to Request a Free Sample Report
The biosimilar mAbs market is segmented into product type, therapeutic area, application, end-user, distribution channel and region. Based on product type, the market is segmented into bevacizumab biosimilars, rituximab biosimilars, trastuzumab biosimilars and other monoclonal antibody biosimilars. Based on therapeutic area, the market is segmented into oncology, autoimmune diseases, infectious diseases, respiratory diseases and other therapeutic areas. Based on application, the market is segmented into hospital pharmacies, retail pharmacies, specialty clinics and contract manufacturing organizations.
Based on end-user, the market is segmented into hospitals, diagnostic centers, research institutes, biotechnology & pharmaceutical companies and others. Based on distribution channel, the market is segmented into direct sales, distributors and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Trastuzumab biosimilar sales account for the largest biosimilar mAbs market share because they meet an established medical demand, compatibility with existing medical protocols and the preference of both healthcare payers and providers based on proven efficacy. In addition, large scale production of the drug and regulatory approval of the drug will assure availability for hospital formularies providing an opportunity for the continued priority of trastuzumab biosimilars. This will provide assurance of long-term market leadership of trastuzumab biosimilars and the potential for market stability through predictable clinical outcomes and cost savings.
As per biosimilar monoclonal antibody market analysis, the rituximab biosimilars segment of the oncology market has recently been identified as the fastest growing segment due to a growing number of approved oncology and autoimmune indications. Additionally, there is currently a growing biosimilar mAbs market trend toward increased use of Rituximab biosimilars in community practice, specialty clinics, and leveraging regulatory momentum to improve accessibility.
As per biosimilar monoclonal antibody market outlook, hospital pharmacies area controls the majority of the biosimilar monoclonal antibody market by combining the procurement of mAb and the administration of mAb from a clinical perspective. By having the purchasing power combined with the infusion infrastructure of the hospital, as well as the infrastructure of the multidisciplinary team, the hospital pharmacy leads the way in terms of mAb biosimilar delivery and use.
As per biosimilar monoclonal antibody market forecast, specialty clinics are the fastest growing segment with the increase in outpatient infusion centers and disease specific practices expanding their capacity to administer biologics, provide convenience, and have sufficient overhead. The availability of clinicians with specific clinical expertise, ease of scheduling, and payers willing to support outpatient care are all driving factors that are leading to an increase in the adoption of mAb biosimilars. Thereby creating new access points for patients and new commercial models driving the acceleration of market growth.
To get detailed segments analysis, Request a Free Sample Report
As per biosimilar monoclonal antibody market regional outlook, Europe continues to lead in monoclonal antibody biosimilar assets because of its established regulatory framework, extensive experience in the development of biopharmaceuticals through manufacture and the ability to utilize a collaborative payer environment to facilitate uptake of biosimilars. Additionally, strong networks of clinical research and existing successful policy frameworks have created a level of confidence for both clinicians and patients around the product.
Also, the extensive experience contract manufacturers have in the transfer of technology, and the production of biosimilars has developed a scalability to production. Pan-regional purchasing strategies and reimbursement processes help develop a clearer pathway to the market. The presence of a created ecosystem consisting of specialized developers, specialized service providers, and academic research centres leads to accelerated development of comparator studies and generation of real-world evidence.
Furthermore, since there is a collective emphasis amongst all players on quality standards and lifecycle management practices this provides little or no barriers to uptake, thereby allowing both local and international companies the ability to compete continuously in the market and provide for new line extensions.
Germany Biosimilar Monoclonal Antibody Market
The biosimilar mAbs market in Germany also benefits from an established base of industry, strong manufacturing capabilities and close collaboration between the academic sector and industry. These capabilities combine to provide mechanisms for payers to build clinician confidence and support interchangeability for therapies by aligning both clinical guidelines. Moreover, the existing network of specialized service providers and experienced contract manufacturers support efficient timelines for the development and scale-up of biosimilars. The existing clarity provided by the regulatory system allows for strengthening of the existing systems for stakeholder engagement processes, thereby broadening the ability of different businesses to have diverse portfolios and attract more investments, thereby allowing for more access to biologic therapies throughout all potential treatment paths.
United Kingdom Biosimilar Monoclonal Antibody Market
The biosimilar mAbs market in the UK is supported by an integrated healthcare system that provides a pathway for adoption via procurement policies and clinical guidance. In addition, there is significant evidence of generation and collaboration between academics and manufacturers; thus, clinical prescriber confidence is enhanced through these activities. The dialogue between the AMV, AMV/AM and manufacturers provide for a transparent pathway to market. Existing manufacturing capability and workforce directly impact reliability of supply. Initiatives that support improving access and providing cost-effective therapeutic alternatives to existing therapies have resulted in increased adoption of biosimilars in acute hospital settings.
France Biosimilar Monoclonal Antibody Market
As per biosimilar monoclonal antibody market regional forecast, France market is supported by a comprehensive healthcare infrastructure, focusing on regional centres of excellence and integrated care networks. Collaborative partnerships among regulators, clinicians and payers support therapeutic interchange and formulary inclusion. The development of homegrown manufacturing and partnerships with international manufacturers has created a resilient supply chain. Educational initiatives and evidence generated in support of the biosimilar medication class have enhanced clinician confidence, thereby supporting a broader adoption of biosimilars across national hospital systems, but also with a continuing emphasis on quality and pharmacovigilance.
As per biosimilar mAbs industry analysis, North American biosimilar monoclonal antibodies have expanded rapidly due to the market being ready, a high-quality clinical trial infrastructure, and the possibility of receiving reimbursement for biologics that are less expensive than existing drugs. Clinical trial networks, both academic and private, and evidence from routine clinical practice provide the means for comparative studies. Established regulatory pathways have created a clear pathway for developers. Health systems and large integrated providers have developed formulary and contracting strategies that promote growth in the market.
U.S. Biosimilar Monoclonal Antibody Market
In the United States, the biosimilar monoclonal antibody market can leverage a mature health care ecosystem consisting of many clinical research networks and sophisticated payer arrangements that support the commercialization and development of complex therapies. The commercial development of biosimilar mAbs has been supported by public and private investments and through collaboration between biotech and large providers. Large established manufacturing services and supply chains enable scalability.
Canada Biosimilar Monoclonal Antibody Market
In Canada the biosimilar monoclonal antibody market can leverage a market driven by payers where provincial procurement and formularies drive the behaviour of physicians with respect to prescribing biosimilars. Collaboration between academia and manufacturers facilitates biosimilar development and production locally. Collaboration through stakeholder forums and specialist focused educational programming supports the confidence of prescribers in using biosimilars. Distribution partnerships and supply chain planning facilitate reliable access to mab biosimilars in urban centres. Policy environments that focus on quality and value have been created to support reimbursement and formulary inclusion of biosimilars, thereby providing access to patients.
In the Asia-Pacific Region, companies are making a framework-based effort to create biased, targeted policy support; build a local domestic manufacturing infrastructure; and increase clinical research capacity to develop the biosimilar monoclonal antibody market. The coordination of emphasis by governments and companies alike on creating regulatory clarity and developing streamlined approval pathways that follow global harmonization standards will open the local and regional markets for investors. The skills and capabilities of workers in the production of monoclonal antibody biosimilars; advancements in biopharmaceutical research; as well as technology transfer programs improve product quality and will shorten the amount of time required to develop a monoclonal antibody biosimilar.
In addition, strategic partnerships between biopharmaceutical companies located in the Asia-Pacific Region and internationally recognized companies will create opportunities for sharing knowledge and commercializing biopharmaceutical products faster than if they were developed by individual companies in the region.
Japan Biosimilar Monoclonal Antibody Market
Japan's biosimilar monoclonal antibody market is characterized by a world-class capability to advance the science of biologics and has high standards for manufacturing quality and compliance with applicable regulations. In addition, Japan provides collaborative platforms for universities, domestic companies, and multinational companies to provide opportunities for research and comparative studies; provide technology transfer opportunities through collaboration. Also, there is a focus within Japan on building skills in the workforce and establishing quality management systems, which are essential components of establishing supply chain resiliency.
South Korea Biosimilar Monoclonal Antibody Market
South Korea's biosimilar monoclonal antibody market benefits from government support for biotechnology. The South Korean government supports forward-looking measures that include helping to establish manufacturing capabilities in South Korea. Collaborations among the Korean National Institute of Health, pharmaceutical companies, and contract manufacturers have helped accelerate the development and commercialization of both generic and biosimilar monoclonal antibodies. Regulatory reform and achieving compliance with international quality standards have resulted in increased confidence among developers of biosimilar monoclonal antibodies. In addition, investments in workforce skills and bioprocess engineering have contributed to ensuring the quality of biosimilar monoclonal antibodies.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Expanding Patient Access Programs
Favorable Regulatory Pathways
Complex Manufacturing Processes
Prescribing Hesitancy and Interchangeability Concerns
Request Free Customization of this report to help us to meet your business objectives.
The competitive environment in the global mAb biosimilar industry is increasingly focused on both strategic mergers and acquisitions (M&A) as well as expanded licensing agreements that focus on establishing the ability to access regulatory reviews and commercialization quickly through the capacity expansions of contract development and manufacturing organizations (CDMOs). Examples of these include Biocon's acquisition of the global biosimilars business of Viatris and Henlius' licensing agreement and supply agreement with Organon. In addition to this, small strategic investments and joint partnerships with other CDMOs (as in the case of Piramal working with Yapan Bio) have made it possible for start-ups to actively compete head-to-head in the complex development of biosimilars for oncology mAb therapies.
Emerging Market Expansion
Adoption of Real-World Evidence
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global mab biosimilar market is propelled by regulatory clarity and scalable manufacturing as a key driver that reduces uncertainty and attracts entrants, while a restraint remains the complex manufacturing processes required to match originator quality. The dominating region is Europe, supported by aligned regulations and procurement frameworks, and the dominating segment is trastuzumab biosimilars owing to established clinical need and formulary adoption. A second driver accelerating growth is AI enabled development that shortens timelines and improves manufacturability, together with expanding patient access programs and competitive pricing which continue to broaden uptake worldwide across hospital and specialty clinic channels.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 689.5 Million |
| Market size value in 2033 | USD 1344.24 Million |
| Growth Rate | 7.7% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered | |
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Biosimilar Monoclonal Antibody Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Biosimilar Monoclonal Antibody Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Biosimilar Monoclonal Antibody Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Biosimilar Monoclonal Antibody Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Biosimilar Monoclonal Antibody Market size was valued at USD 689.5 Million in 2024 and is poised to grow from USD 742.59 Million in 2025 to USD 1344.24 Million by 2033, growing at a CAGR of 7.7% during the forecast period (2026-2033).
Key vendors in the Biosimilar Monoclonal Antibody Market include major pharmaceutical and biopharmaceutical companies such as Amgen, Pfizer, Novartis, Samsung Bioepis, Celltrion, Biocon, and Viatris. These players compete through strong pipelines, strategic collaborations, and advanced manufacturing capabilities to expand global market presence.
The key driver of the Biosimilar Monoclonal Antibody Market is the increasing demand for cost-effective alternatives to expensive biologic therapies. Rising healthcare costs, growing prevalence of chronic diseases, and patent expirations of blockbuster biologics are driving the adoption of biosimilar monoclonal antibodies globally.
A key market trend in the Biosimilar Monoclonal Antibody Market is the rapid expansion of biosimilar pipelines driven by patent expirations of major biologics. Increasing focus on cost-effective therapies, strategic collaborations, and advancements in bioprocessing technologies is enhancing accessibility, affordability, and global adoption.
Europe accounted for the largest share in the Biosimilar Monoclonal Antibody Market, driven by early regulatory approvals, strong healthcare infrastructure, and high adoption of biosimilars supported by favorable government policies.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
